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ABSTRACT
Introduction: The objective of this study was to
compare differences in glucoregulation,
frequency of hypoglycemic episodes, glucose
variability and lipid profiles of inpatients with
poorly regulated type 1 diabetes mellitus
(T1DM) after evening versus morning glargine
application.
Methods: Eighteen patients with poorly
regulated T1DM, glycated hemoglobin (Hba1c)
levels C7% and frequent nocturnal and/or
morning hypoglycemic episodes were included
in this study. There was a 12-week screening
phase where patients continued their usual
insulin regimen and were encouraged to
achieve optimal glycemic control; however, all
patients maintained HbA1c values C7% and
continued to have frequent nocturnal and/or
morning hypoglycemic events and were
therefore transitioned to morning application
of insulin glargine for 12 weeks. The primary
outcome was to investigate changes in HbA1c
values 12 weeks after the transition. The
secondary outcome was to evaluate the effect
of transition on glucose variability, incidence of
hypoglycemic episodes, insulin doses, lipid
profile and weight. Data were analyzed using
paired Student’s t test and Pearson correlation.
Results: After the transition, there was no
significant change in total daily dose of basal
insulin (p 0.114) and the average body weight
remained unchanged, while significant
reduction of HbA1c was present (8.02 ± 0.5 vs.
7.4 ± 0.3%) (p\0.01) resulting in a decrease in
nocturnal and daytime hypoglycemic episodes
per month per person (p\0.01). Parameters of
glucose variability (glycemic standard
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deviations and J-index) were also improved
after transition period (p\0.01). As for the
lipid profile, increase of high-density
lipoprotein cholesterol and decrease of
triglycerides (p\0.01) were noticed, while
other lipid parameters remained unaffected.
Furthermore, insignificant association of basal
insulin dose with HbA1c values regardless of the
time of administration was observed.
Conclusion: In patients with poorly regulated
T1DM, transition to morning application of
glargine improved glucoregulation (including a
decrease in HbA1c, glucose variability and
number of nocturnal hypoglycemic episodes),
followed by favorable changes in lipid profile
without affecting body weight. These effects
were associated with the time of application,
but not with the insulin dose.
Keywords: Basal insulin; Diabetes type 1;
Glucoregulation; Hypoglycemia; Lipid profile;
Morning administration
INTRODUCTION
The average individual with type 1 diabetes
mellitus (T1DM) experiences about two
episodes of symptomatic hypoglycemia per
week [1]. Severe hypoglycemia (requiring help
for recovery) has an annual prevalence of
30–40% and an annual incidence of 1.0–1.7
episodes per patient per year [1]. This risk is
increased markedly with the strict glycemic
control and leads to impaired quality of life.
There have only been a small number of
studies performed on patients with T1DM
evaluating whether the timing of insulin
glargine administration (morning or bedtime)
would affect glucoregulation and/or frequency
of hypoglycemic episodes [2, 3]. Results
obtained from those studies indicated that
there was no difference in glycated
hemoglobin (HbA1c) values regarding the time
of administration, although nocturnal
hypoglycemias were less frequent in a group
who administered glargine in the morning [2,
3]. The objective of this prospective
observational study was to investigate whether
the transition from bedtime to morning insulin
glargine administration has a beneficiary effect
on glucose regulation and hypoglycemic
episodes as well as lipid profiles in patients
with poorly regulated T1DM.
PATIENTS AND METHODS
A total of 18 patients with poorly controlled
T1DM were recruited for this pilot study during
routine outpatient visits (from County Hospital
Cakovec, University Hospital Center Osijek and
University Hospital Center ‘‘SestreMilosrdnice’’
Zagreb). In this observational longitudinal
study, 18 patients (9 females, 9 males) that
had been treated with an intensified insulin
regimen (glargine at bedtime (09:00 or
10:00 p.m.) ? lispro/aspart/glulisine prior to
meals) for at least 1 year with an average
Hba1c value C7%, frequent nocturnal and/or
morning hypoglycemic episodes and high
pre-dinner BG (blood glucose) values
(C7.1 mmol/L) were directly switched to
morning administration (09:00 or 10:00 a.m.)
of insulin glargine injection. The basal insulin
was titrated using a simple algorithm seeking a
target fasting plasma glucose B5.5 mmol/L,
while dosages of short acting insulin were
calculated according to carbohydrates and
pre-meal BG values. Prior the transition of
glargine administration, there was a 12-week
screening phase where patients continued their
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usual insulin regimen and were encouraged to
achieve optimal glycemic control. Patients were
also instructed to obtain 4-point and 8-point BG
values determined by self-monitoring BG
(SMBG). In addition, frequencies of
hypoglycemic events were assessed using
standard patient diaries. Frequent
hypoglycemia was defined as approximately
two to four times per week or more, nocturnal
hypoglycemia applied to hypoglycemic events
from bedtime to 06:00 a.m. whereas morning
hypoglycemia encompassed all events from
06:00 a.m. until breakfast [4]. Hypoglycemic
episodes were defined as events with symptoms
consistent with hypoglycemia in which the
patient had a BG level\3.9 mmol/L or the
event was associated with prompt recovery
after oral carbohydrate or intravenous glucose
or subcutaneous glucagon administration and
required another person’s assistance (severe
hypoglycemic episode). In addition, all events
that were not accompanied by typical
symptoms of hypoglycemia but a measured
plasma glucose concentration was B3.9 mmol/
L were included [4]. At the end of the 12-week
screening period, HbA1c levels and lipid profiles
were determined. SMBG values and patient
diaries were also assessed. All patients included
at the screening phase maintained poor
regulation of diabetes with an HbA1c
level C7% (mean value 8.02 ± 0.5%). They also
continued to have frequent nocturnal and/or
morning hypoglycemic events and were
therefore transitioned to morning application
of insulin glargine. The primary objective was to
investigate changes in HbA1c values 12 weeks
after the transition (the end point). The
secondary objective was to evaluate the effect
of transition on glucose variability, incidence of
hypoglycemia, insulin doses, lipid profile and
weight.
Statistical Analysis
Results were analyzed using descriptive
statistical analysis. Continuous variables were
summarized using sample size, mean and
standard deviation values. Significance was
declared at a two-sided 0.01 level, unless
otherwise specified. The difference between
continuous variables at the beginning and at
the end of observation was analyzed by paired
student’s t test for parametric analysis, while
Wilcoxon signed ranks test was used for
nonparametric analysis (both were used for
comparison of hypoglycemic events). Pearson’s
correlation coefficients were computed to
estimate the magnitude of the association
between variables of interest. Statistical
analyses were performed using SPSS software
for Windows (version 16.0, SPSS Inc., Chicago
IL, USA).
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
Additional informed consent was obtained
from all patients and their identifying
information is included in this article.
RESULTS
A total number of 18 patients with T1DM were
analyzed. Patients’ average age was
33.1 ± 9.1 years and the average duration of
diabetes was 19.7 ± 12.0 years on intensified
therapy with insulin analogs. Table 1 shows a
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comparison of the data obtained at baseline, at
transition and at 12 weeks after the transition. A
significant reduction of mean HbA1c values
from baseline to end point was observed
(8.02 ± 0.60 vs. 7.45 ± 0.38%, p\0.01).
Regarding glycemic control based on SMBG
values (4 point and 8 point), a decrease in
pre-lunch (p\0.01) and pre-dinner (p\0.01)
BG values were registered, accompanied with an
increase in fasting glycemia (p\0.01). A total
daily dose of basal insulin analog remained
unaffected (23.35 ± 5.90 vs. 24.24 ± 6.96
international units p = 0.114) when compared
to initial dose as well as body weight and body
mass index. Furthermore, the proportion of
patients experiencing morning and nocturnal
hypoglycemic events was significantly
decreased at the end of a 12-week period after
Table 1 Characteristics of the subjects at baseline, at transition and 12 weeks after the transition
Variable Baseline (12 week before
transition)
At transition 12 weeks after
transition
HbA1c (%) 8.02 ± 0.60 8.08 ± 0.57 7.45 ± 0.38*
Fasting BG (mmol/L) 4.78 ± 0.60 4.64 ± 0.66 6.25 ± 0.31*
Postprandial BG (mmol/L) 6.76 ± 0.80 6.65 ± 0.75 6.56 ± 0.57
Pre-lunch BG (mmol/L) 7.41 ± 0.80 7.40 ± 0.81 6.81 ± 0.46*
Pre-dinner BG (mmol/L) 10.31 ± 1.20 9.84 ± 0.74 6.87 ± 0.38*
BMI (g/cm2) 23.54 ± 3.18 23.54 ± 3.18 23.52 ± 2.46
Body weight (kg) 70.33 ± 15.21 70.33 ± 15.21 70.10 ± 13.93
Total cholesterol (mmol/L) 4.5 ± 0.40 4.37 ± 0.52 4.30 ± 0.47
Triglycerides (mmol/L) 2.1 ± 0.60 1.93 ± 0.50* 1.72 ± 0.37*
HDL (mmol/L) 1.01 ± 0.09 1.07 ± 0.17 1.20 ± 0.10*
LDL (mmol/L) 3.30 ± 0.40 3.14 ± 0.44 3.07 ± 0.44
Daily dose of basal insulin (IU) 24.60 ± 6.60 23.35 ± 5.90 24.24 ± 6.96
Proportion of patients experienced morning
hypoglycemia (n/%)
18/100.0 18/100.0 11/61.0II
Proportion of patients experienced nocturnal
hypoglycemia (n/%)
12/66.6 13/72.2 5/27.7II
Average number of morning hypoglycemias per
month per patient
4.30 ± 1.60 3.66 ± 1.40 0.63 ± 0.74§
Average number of nocturnal hypoglycemias per
month per patient
0.70 ± 0.60 0.69 ± 0.51 0.22 ± 0.39§
Total number of morning hypoglycemias 78 66 12*
Total number of nocturnal hypoglycemias 13 13 4*
HbA1c glycated hemoglobin, BG blood glucose, BMI body mass index, HDL high-density lipoprotein, LDL low-density
lipoprotein, IU international unit
Paired Student’s t test; * p\0.01 vs. baseline;  p\0.01 vs. transition; Wilcoxon Signed Ranks Test;  p\0.01 vs. baseline;
§ p\0.01 vs. transition; Fisher exact test; II p\0.01 vs. transition
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transition (p\0.01). The average number of
morning and nocturnal hypoglycemic episodes
per month per patient and total number of
overall hypoglycemic events were also
significantly reduced (p\0.01). Significant
changes regarding lipid profiles were also
observed such as an increase of high-density
lipoprotein cholesterol (1.07 ± 0.17 vs.
1.20 ± 0.10 mmol/L, p\0.01) and decrease of
triglyceride levels (1.93 ± 0.50 vs.
1.72 ± 0.37 mmol/L, p\0.01), while total and
low-density lipoprotein cholesterol levels were
not changed (Table 1).
DISCUSSION
Former studies investigating the effect time of
administration in patients with T1DM
demonstrated a similar reduction in
HbA1c with morning and bedtime insulin
glargine dosages as the present study [2, 3];
however, those studies showed no significant
difference in the frequency or duration of
hypoglycemia during the day or the night
irrespective of the timing of glargine injection
[3]. In the present study, a significant reduction
of HbA1c was registered at 12 weeks after initial
transition, without changes in insulin doses and
with lower rates of hypoglycemic episodes
(especially in the morning). Decrease in
pre-lunch and pre-dinner BG values and an
increase in fasting glycaemia were also
observed. This suggests that an improvement
of overall glycemic control was achieved due to
a decrease of glucose variability regardless of
higher fasting BG values. Since glucose
fluctuation is a well-recognized glycemic
disorder next to hyperglycemia both fasting
and postprandial and is held accountable for
excessive glycation and generation of oxidative
stress, its decrease could potentially have an
important impact on development of chronic
complications [5].
Recently, Porcellati et al. demonstrated that
the pharmacodynamics of insulin glargine
differs depending on time of administration.
The 24-h glucose infusion rate area under the
curve (AUC [0–24 h]) was similar in evening and
morning studies; however, morning
administered insulin activity was greater in the
first 0–12 h, while with evening administration
the activity was greater in the 12–24-h period
following dosing in patient with type 2 diabetes
mellitus [6]. It was speculated that these results
could reflect the impact of circadian changes in
insulin sensitivity in type 2 diabetes (lower in
the night-early morning). The question remains
as to whether the same explanation could be
applied to patients with T1DM in the present
study. The variability of the dawn phenomenon
is an individual characteristic and should be
considered prior to reaching any therapeutic
decisions aimed at correcting fasting
hyperglycemia [7]. Obviously, increases in
bedtime doses of hypoglycemic agents may
correct early morning hyperglycemia but may
also be associated with undesirable nocturnal
and early morning hypoglycemia as well as
reactive hyperglycemia during the daytime
leading to overall poor glycemic control and
acute glucose fluctuations.
The present study has several limitations.
The number of subjects was small and the
treatment period short. It is also an
observational study and thus potentially
biased since study effect cannot be excluded
although there was a 3-month run in period
with strict self control. A large-scale, long-term
randomized clinical study is required for
confirmation of the present results.
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CONCLUSION
In summary, transition from bedtime to
morning basal insulin administration in
patients with poorly regulated T1DM could
possibly improve glucoregulation and reduce
the number of nocturnal and morning
hypoglycemic episodes without affecting body
weight, while at the same time inducing
favorable changes in glucose variability and
lipid profile. The effect on glycemic control was
not associated with insulin dose but only with
the time of basal insulin application.
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